Salestools LogoSalestools
Agenti IA Salestools
Soluzioni
Risorse
Azienda
Prezzi
Salestools Logo

Salestools

L'agente IA #1 per team di vendita e Go-to-Market. Vendi di più, più velocemente, con meno sforzo.

Prodotto

  • Agenti di vendita IA
  • Dati di intenzione
  • Dati Tecnologici
  • Tracciamento Visitatori
  • Co-Pilota
  • Vendita Sociale

Soluzioni

  • Servizio Clienti
  • E-commerce
  • SaaS
  • Impresa
  • Piccole Imprese

Risorse

  • Il rapporto
  • Documentazione
  • Riferimento API
  • Centro assistenza
  • Blog
  • Casi studio
  • Webinar

Azienda

  • Chi siamo
  • Carriere
  • Stampa
  • Contatto
  • Partner

Le nostre sedi

  • New York, HQ
  • Bucarest, Laboratorio di Ricerca IA
  • Zug, Svizzera

© 2025 Salestools. Tutti i diritti riservati.

Termini sui Dati e SicurezzaPolitica sulla privacyTermini di servizio
Tutti i sistemi operativi
Salestools LogoSalestools
Agenti IA Salestools
Soluzioni
Risorse
Azienda
Prezzi
Back to The Report
Biotech

Enveda Biosciences

Enveda Biosciences Raises $130M Series C

$130M Series C
Total Raised
2019
Founded
80-150
Employees
Boulder, CO
Updated October 23, 2025
2 min read

Quick Facts

Valuation
Undisclosed

Enveda Biosciences Raises $130M Series C

Biotechnology company using AI and metabolomics to discover new drugs from natural products and medicinal plants

Key Highlights

  • Funding Amount: $130M Series C
  • Valuation: Undisclosed
  • Headquarters: Boulder, CO
  • Founded: 2019
  • Employees: 80-150
  • Total Raised: $175M

About the Funding Round

Enveda Biosciences has successfully closed $130M Series C in funding, marking a significant milestone in the company's growth trajectory. This investment will enable the company to accelerate product development, expand market reach, and strengthen its position in the biotech sector.

Investor Syndicate

The round was backed by a prestigious group of investors:

  • FPV Ventures
  • Kinnevik
  • Lux Capital

This diverse group of investors brings not only capital but also strategic expertise and valuable networks that will help Enveda Biosciences achieve its ambitious goals.

Market Opportunity

The biotech market continues to experience rapid growth, driven by increasing demand for innovative solutions and digital transformation across industries. Enveda Biosciences's unique approach and proven technology position it well to capture significant market share in the coming years.

Company Background

Founded in 2019 and headquartered in Boulder, CO, Enveda Biosciences has established itself as an innovative player in the biotech space. With 80-150 employees, the company has built a strong team focused on delivering exceptional value to customers.

Next Steps

With this new funding, Enveda Biosciences plans to:

  • Accelerate product development and innovation
  • Expand into new markets and geographies
  • Grow the team across engineering, sales, and operations
  • Strengthen partnerships with key industry players
  • Scale infrastructure to support rapid growth

Industry Impact

This funding round represents a strong vote of confidence in Enveda Biosciences's vision and execution. The investment will help drive innovation in the biotech sector and create new opportunities for customers and partners.


For more information about Enveda Biosciences, visit their website or contact their press office.

Key Investors

FPV Ventures
Venture Capital
Venture capital firm
Kinnevik
Strategic Investor
Swedish investment firm
Lux Capital
Venture Capital
Venture capital firm backing science and technology ventures

Topics

Venture Capital(911)Series(545)BiotechFunding RoundCO

About the Author

Sarah Kim
Sarah Kim
Healthcare and biotech investment analyst with expertise in Series B+ rounds and strategic partnerships.

Related Company Reports

Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology

Vir Biotechnology Raises $250M

Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$250M